NES
MYGN icon

New England Securities’s Myriad Genetics MYGN Stock Holding History

New England Securities’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$26K Sell
766
-157
-17% -$5.57K 0.01% 790
2014
Q3 		$36K Sell
923
-479
-34% -$17.9K 0.01% 718
2014
Q2 		$55K Buy
1,402
+212
+18% +$7.89K 0.02% 593
2014
Q1 		$41K Buy
1,190
+357
+43% +$11.1K 0.02% 617
2013
Q4 		$17K Buy
833
+540
+184% +$13.7K 0.01% 879
2013
Q3 		$7K Buy
293
+69
+31% +$1.96K ﹤0.01% 1087
2013
Q2 		$6K Buy
+224
New +$6.49K ﹤0.01% 1006

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

New England Securities's MYGN Position: Q4 2014 in Review

New England Securities reduced its Myriad Genetics (MYGN) stake by 17% in Q4 2014, selling an estimated $5.57K and leaving 766 shares worth $26K. The position accounts for 0.01% of the portfolio, ranked #790.

New England Securities first reported a position in MYGN in Q2 2013 and has held it in 7 quarters since. The position peaked at $55K in Q2 2014. 272 funds tracked by Wall St. Rank hold MYGN as of Q4 2014.

  • New England Securities held 766 shares of Myriad Genetics worth $26K as of Q4 2014.
  • New England Securities sold 157 Myriad Genetics shares in Q4 2014, an estimated $5.57K.
  • Myriad Genetics made up 0.01% of New England Securities's portfolio in Q4 2014, its #790 holding.
  • New England Securities first reported a position in Myriad Genetics in Q2 2013 and has held it in 7 quarters since.
  • New England Securities's Myriad Genetics position peaked at $55K in Q2 2014.
  • 272 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2014.

Based on New England Securities's 13F filing for Q4 2014, filed 26 Jan 2015.